Revvity jumps after lifting 2025 adjusted profit outlook

Medical equipment maker Revvity's RVTY.N shares surge 8.6% to $112.85, touching a over 9-month high

Co said late on Monday its 2025 adjusted profit per share will exceed its prior forecast of $4.90 to $5.00

RVTY expects Q4 revenue of around $772 million, above analysts' estimates of $760.3 million

Co sees 2025 revenue growing at 4% to $2.86 billion, above estimates of $2.84 billion

"We are curious if life sciences came in a tad better, given peer Danaher DHR.N noted slightly better pharma sentiment," Evercore ISI says

"Given the improved Q4 exit rate, we wonder if RVTY points to high end of prior issued 2-3% outlook for FY26," brokerage adds

As of last close, stock has fell 15.3% in past 12 months